{"groups":[{"description":"Participants with DLBCL received Selinexor in different Schedules; Schedule 1: \\<= 12 milligram per square meter (mg/m\\^2) per orally (PO) alternating 3 times per week with twice weekly dosing (1 day between doses); Schedule 2: \\> 12 mg/m\\^2 PO 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly (1 day between doses) during Weeks 1 and 2; Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab intravenous (IV) once weekly for Weeks 1-4 during different cycles. Each cycle was of 28 days (Schedule 8: 21 days of cycle) or 10 scheduled selinexor doses.","id":"FG000","title":"Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Participants with NHL received Selinexor in different Schedules; Schedule 1: \\<= 12 mg/m\\^2 PO alternating 3 times per week with twice weekly dosing (1 day between doses); Schedule 2: \\> 12 mg/m\\^2 PO 3 times weekly for week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs 1 day apart (Schedule 3); Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 days between doses) to evaluate vs twice weekly (Schedules 3, 4, 5, and 6); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly \\[1 Day between doses\\] during weeks 1 and 2; Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab IV once weekly for Weeks 1-4) during different cycles. Each cycle was of 28 days (Schedule 8: 21 days of cycle) or 10 scheduled selinexor doses.","id":"FG001","title":"Non-Hodgkin Lymphoma (NHL) Excluding DLBCL"},{"description":"Participants with MM received Selinexor in different Schedules; Schedule 1: \\<= 12 mg/m\\^2 PO alternating 3 times per week with twice weekly dosing (1 Day between doses); Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; 3 doses (36 mg/m\\^2 total) in the 1-week run-in period; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 6: \\>= 35 mg/m\\^2 PO twice weekly with dexamethasone (20 mg twice weekly) on Days of twice weekly Selinexor dosing; Schedule 11: Group A: 40 mg; Group B: 60 mg; Group C: 80 mg twice weekly (Weeks 1, 2, and 3) at 3 fixed dose levels during different cycles. Each cycle was of 28 days or 10 scheduled selinexor doses.","id":"FG002","title":"Multiple Myeloma (MM)"},{"description":"Participants with AML received Selinexor in different Schedules; Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3), Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 Days between doses) to evaluate vs. twice weekly (Schedules 3, 4, 5, and 6); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly (1 Day between doses) during Weeks 1 and 2; Schedule 10: \\>= 55 mg/m\\^2 PO twice weekly PO (Weeks 1 and 2) in participants with AML/18-Day treatment-free interval) during different cycles. Each cycle was of 28 days (for schedule 8: 21-day of cycle) or 10 scheduled selinexor doses.","id":"FG003","title":"Acute Myeloid Leukemia (AML)"},{"description":"Participants with other hematological malignancies (Acute lymphoblastic leukemia \\[ALL\\], Chronic myelogenous leukemia \\[CML\\] and chronic lymphocytic leukemia \\[CLL\\]) received Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly \\[1 day between doses\\]; Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 Days between doses) to evaluate vs. twice weekly (Schedules 3, 4, 5, and 6); Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab IV once weekly for Weeks 1-4 during different cycles. Each cycle was of 28 days or 10 scheduled selinexor doses.","id":"FG004","title":"Other Hematological Malignancies (ALL, CML and CLL)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"Need of treatment not allowed per protocol"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"0"}],"type":"Investigator discretion"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"}],"type":"Other treatments became available"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"}],"type":"Intercurrent illness"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"Non-Compliance with study procedures"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"14"},{"groupId":"FG004","numSubjects":"4"}],"type":"Consent withdrawn by participant"},{"reasons":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"37"},{"groupId":"FG003","numSubjects":"57"},{"groupId":"FG004","numSubjects":"9"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"6"}],"type":"Incidence or severity of Adverse events"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"81"},{"groupId":"FG003","numSubjects":"95"},{"groupId":"FG004","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"81"},{"groupId":"FG003","numSubjects":"95"},{"groupId":"FG004","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 286 participants were enrolled out of which 1 participants with MM never treated due to disease progression prior to dose initiation and 285 participants received treatment in 11 different schedules. The schedules were either 28 days (Schedules 1-7, 9-11) or 21 days (Schedule 8) per cycle and participants were treated once weekly (Schedule 7), twice weekly (Schedules 3-6, 8-11) or three times weekly alternating with 2 times weekly (Schedules 1, 2).","recruitmentDetails":"The study was conducted at 12 sites in United States, Canada and Europe between 23 July 2012 (first participant treated) and 13 October 2015 (last participant completed)."}